

DAFTAR PUSTAKA

- Alhazzani, W., Alshamsi, F., Belley-Cote, E., Heels-Ansdell, D., Brignardello-Petersen, R., Alquraini, M., (2018). Efficacy and Safety of Stress Ulcer Prophylaxis in Critically Ill Patients: a Network Meta-Analysis of Randomized Trials, *Intensive Care Med*, 44:1-11.
- Amaral, M.C., Favas, C., Alves, J.D., Riso, N., dan Riscado, M.V., 2010. Stress related mucosal disease: Incidence of bleeding and the role of omeprazole in its prophylaxis. *European Journal of Internal Medicine*, **21**: 386-388
- American Society of Health-System Pharmacist. (1999). ASHP therapeutic guidelines on stress ulcer prophylaxis. ASHP Commission on Therapeutics and approved by the ASHP Board of Directors on November 14, 1998. American Journal of Health-System Pharmacy: *AJHP: Official Journal of the American Society of Health-System Pharmacists*, 56(4), 347–379
- Andersson T, Hassan-Alin M, Hasselgren G, Röhss K, Weidolf L. (2001) Pharmacokinetic studies with esomeprazole, the (S)-isomer of omeprazole. *Clin Pharmacokinetik* 40:411-426.
- Asano S, Yoshida A, Yashiro H. (2004). The cavity structure for docking the K⁺-competitive inhibitors in the gastric proton pump. *Journal Of Biological Chemistry*, 279:13968-13975
- Avendano-Reyes, J. M., & Jaramillo-Ramirez, H. (2014). Prophylaxis for stress ulcer bleeding in the intensive care unit. *Revista de Gastroenterologia de Mexico*, 79(1):50–55.
- Barkun, A. N., Adam, V., Martel, M., & Bardou, M. (2013). Cost-effectiveness analysis: stress ulcer bleeding prophylaxis with proton pump inhibitors, H₂ receptor antagonists. Value in Health: *The Journal of the International Society for Pharmacoeconomics and Outcomes Research*, 16(1), 14–22.
- Barkun, A.N., Saltzman, J.R., Martel, M., dan Leontiadis, G.I., (2021). ACG Clinical Guideline: Upper Gastrointestinal and Ulcer Bleeding. *American Journal of Gastroenterology*, **116**: 899–917.
- Bardou, M., Quenot, J.P., Barkun, A. (2015). Stress related mucosal disease in the critically ill patient. *Nature review gastroenterology & hepatology*, **12** (2), 90-107.
- Chu, Y., Jiang, Y., Meng, M., Jiang, J., Zhang, J., Ren, H., dkk., 2010. Incidence and risk factors of gastrointestinal bleeding in mechanically ventilated patients **1**:

- Conn HO, Poynard T. 2014. Kortikosteroid dan tukak lambung:meta-analisis efek samping selama terapi steroid. *Journal medicinal*:236;619-32
- Cook DJ, Griffith LE, Walter SD. (2001). The attributable mortality and length of intensive care unit stay of clinically important gastrointestinal bleeding in critically ill patients. *Critical care* 5:368-75.
- Cokro,F. dan Jokimawidjaja,J. (2022). Effectiveness of Pompa proton pump inhibitors as a Gastrointestinal bleeding prophylaxis in intensive care unit: Systematic review and meta analisis, *Journal of Urban Health Research*, 1 (1) p.1-11. Available at <https://doi.org/10.25170/juhr.v1i1.3714>
- DiPiro, J.T., Schwinghammer, T.L. and Ellingrod, V.L. (2020). *Pharmacotherapy: A Pathophysiologic Approach, Eleventh Edition*. 11 th edn. New York: McGraw Hill.
- Goodman & Gilman. (2006). *Agent for control of gastric acidity and treatment of stress ulcer*. The pharmacological basic of therapeutics vol 2:899-902
- Kerama, S.K., Okalebo, F.A., Nyamu, D.G., Guantai, E.M., Ndwigah, S.N., dan Maru, S.M., 2014. Risk factors and management of stress ulcer in the critical care unit in a kenyan referral hospital. *African Journal of Pharmacology and Therapeutics*. Vol, 3: 51:61
- Khoshbaten M, Farzin H, Fattahi E, Entezarie AM. (2006). Significant upper GI bleeding in critically ill patients. *The internet journal of gastroenterology*.5:2
- Lexicomp online, (2022). lexi-drug online pompa proton inhibitor, MA:UpToDate Inc, <https://online.lexi.com>. Diakses tanggal 23 September 2023.
- Marie A., C.-B., (2019). *Pharmacotherapy Principles and Practice*, Fifth Edition. McGraw-Hill, New York.
- Messer J, Reitman D, Sacks HS, dkk. 2014. Assosiasi terapi adrenokortikosteroid dan penyakit tukak lambung. *N Engl Journal medicinal*;309:21-4
- Minner P Jr, Katz PO, Chen Y, Sostek M. (2003). Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. *Am J Gastroenterol* 98: 2616–20.
- Mohebbi L, Hesch K. (2009). Stress Ulcer Prophylaxis in Intensive Care Unit. *Pharmacology Notes*. 22(4):373-6.
- Narum, S., Westergren, T., dan Klemp, M., 2014. Corticosteroids and risk of gastrointestinal bleeding: a systematic review and meta-analysis. *BMJ Open*, 4: e004587.
- Octavia, M., Ikawati, Z., dan Andayani, T.M., (2021). The effectiveness and cost of lansoprazole and pantoprazole for stress ulcer prophylaxis in intensive careunit.

Pharmaciana, **11**: 355

- Plummer MP, Blaser AR, Deane AM. (2014). Stress ulceration: prevalence, pathology and association with adverse outcomes. *Critical Care*. 18(2):213.
- Priyanto. (2008). Farmakoterapi & Terminologi Medis. Leskomfit. Jakarta
- Lemeshow, S. dan World Health Organization (Editor), 1990. Adequacy of Sample Size in Health Studies. Published on behalf of the World Health Organization by Wiley ; Distributed in the U.S.A., Canada, and Japan by Liss, Chichester [England] ; New York : New York, NY, USA.
- Robinson M, Fitzgerald S, Hegedus R, Murthy A, Jokubaitis L. (2002). Onset of symptom relief with rabeprazole: a communitybased, open-label assessment of patients with erosive oesophagitis. *Aliment Pharmacol Ther* 2;16: 445–54.
- Shin, J.M. dan Kim, N., (2013). Pharmacokinetics and Pharmacodynamics of the Proton Pump Inhibitors. *Journal of Neurogastroenterology and Motility*, **19**: 25–35.
- Sholihah, R.I. (2019). Evaluasi Penggunaan Obat Golongan PPI (Proton Pump Inhibitor) Pada Penderita GERD; p. 55.
- Sinuraya, R.K, Gondodiputro, S., dan Djuhaeni, H. (2017). Proton pump inhibitors for stress ulcer bleeding prophylaxis in critically ill patients: A cost analysis study. *Asian journal of pharmaceutical and clinical research*, 10:128
- Spirt, M. J., & Stanley, S. (2006). Update on stress ulcer prophylaxis in critically ill patients. *Critical Care Nurse*, 26(1):18–20, 22–28
- Sukengtyas;, D.A.T., Andayani;, T.M. dan Budiarti, L.E. (2017) ‘Kajian Efektivitas Dan Biaya Terapi Penggunaan Omeprazol dan Pantoprazol Sebagai Profilaksis Stress Related Mucosal Disease di icu the Effectiveness and CostAnalysis of Omeprazole and Pantoprazole’, *Jurnal Manajemen dan Pelayanan Farmasi*, 7(2), pp. 57–64.
- Thompson AB. (2009). Are the orally administered proton pump inhibitors equivalent? A comparison of lansoprazole, omeprazole, pantoprazole and rabeprazole. *Curr Gastroenterol Rep* 2: 482–93.
- Vanderhoff BT, Tahboub RM. (2002). Proton pump inhibitors: an update. *Am Fam Physician* 66: 273–80
- Van Rensburg, C.J dan Cheer, S., (2012). Pantoprazole for the treatment of peptic ulcer bleeding and prevention of rebleeding. *Clinical medicine insights: Gastroenterology*, 5:51-60
- Welage, L.S., (2003). Pharmacologic Properties of Proton Pump Inhibitors. *Pharmacotherapy*, **23**: 74S-80S

Zeitoun, A., Zeineddine, M., dan Dimmassi, H., (2011), Stress Ulcer Prophylaxis Guidlines: Are They Being Implemented in Labanase Health Care Centers?, *World Journal of Gastrointestinal Pharmacology and Therapeutic*, 4(2):27–3